| Date | Title | Description |
| 04.08.2026 | Vantage Biosciences Completes Enrollment in Phase 2 SeeClear Study of Oral Oruvestat in Non-Proliferative Diabetic Retinopathy | LONDON, 4 August 2026 - Vantage Biosciences today announced that it has completed patient enrollment in the Phase 2 SeeClear study (VX01-DR-201) of oruvestat (VX-01), an investigational, orally administered inhibitor of amine oxidase copper... |
| 06.07.2026 | ReproNovo announces first participant dosed in EU Phase 2 Trial of RPN-002 for Embryo Implantation | - RPN-002 is an orally administered oxytocin receptor antagonist aiming to improve IVF/ICSI success rates
- The NORDIC study marks an important step in advancing ReproNovo’s global Phase 2 pipeline acrossfertility and women’s health, with f... |
| 22.06.2026 | Oxford BioTherapeutics’ Third Partnered Programme with Boehringer Ingelheim Enters the Clinic and its First (Obrixtamig) Advances to Phase 3 | - First patients dosed with BI 3820768 (OB33), marking third programme from the Oxford BioTherapeutics (OBT)-Boehringer Ingelheim collaboration to enter clinical development
- Obrixtamig reaches late-stage development triggering milestone p... |
| 09.04.2026 | Oxford BioTherapeutics Enters Strategic Collaboration with Bristol Myers Squibb to Discover and Develop Next-Generation T-cell Engagers for Solid Tumours | ▪ Collaboration leverages OBT's proprietary OGAP®-Verify discovery platform and drug development capabilities in alignment with BMS’s expertise to advance selected novel oncology targets
▪ This is OBT’s third major pharma collaboration with... |
| 24.02.2026 | Promatix Biosciences Presents Positive Preclinical Data with First-in-Class PBS293 EGFR×EphA2 Cis-Bispecific ADC Demonstrating Enhanced Tumour Selectivity | London and Cambridge, UK — 24 February 2026 — Promatix Biosciences Ltd (Promatix), an emerging UK-based biotechnology company developing innovative new classes of cancer therapies using cis-bispecific antibodies, today presented positive pr... |
| 24.02.2026 | ALSA Ventures has joined the Investing in Women Code to help advance female entrepreneurship in the UK | ALSA Ventures has joined the Investing in Women Code, a UK Government-backed commitment to improve women entrepreneurs’ access to the tools, resources and finance needed to start and scale.
Women-led and mixed-gender founding teams remain s... |
| 10.12.2025 | Oxford BioTherapeutics Enters into a Strategic Collaboration with GSK to Discover Novel Targets for Antibody-Based Therapeutics for the Treatment of Cancer | ▪ Collaboration leverages OBT's proprietary OGAP®-Verify platform and GSK's drug development expertise to advance multiple selected novel oncology targets
▪ The agreement - OBT's second high-profile pharma collaboration this year - reflects... |
| 11.07.2024 | Epsilogen announces CTA approval for Phase Ib trial of MOv18 IgE in platinum-resistant ovarian cancer |
Phase Ib study expected to initiate in H2 2024
Previously reported Phase I results showedMOv18 IgE to be safe and well tolerated, with evidence of anti-tumour activity
LONDON, 8 July 2024 – Epsilogen, a global leader in the development of ... |
| 02.05.2024 | Epsilogen appoints Ashley Nagle as Chief Business Officer and Peter Finan as Non-Executive Chairman as part of broader company expansion | LONDON, 3 April 2024 – Epsilogen, a global leader in the development of immunoglobulin E (IgE) antibodies to treat cancer, today announces the appointments of Ashley Nagle as Chief Business Officer(CBO) and Peter Finan as Non-Executive Chai... |
| 01.05.2024 | Alek Safarian shares his opinions on the current funding environment for biotech, and introduces ALSA Ventures and its investment philosophy. | ALSA Ventures CEO Alek Safarian recently sat down with BiotechTV to share his views on the current biotech venture capital funding environment in UK and Europe, and where the industry is heading.
|
| 24.10.2023 | Oxford BioTherapeutics announces that partner Boehringer Ingelheim dosed the first patient in a Phase 2 trial investigating BI 764532 (OBT620) for the treatment of small cell lung cancer (SCLC) and ot... | BI 764532 was discovered using OBT’s proprietary OGAP® platform, the world's largest, cancer specific, membrane protein library used to identify novel, high specific antigens for cancer targets |
| 03.10.2023 | Oxford BioTherapeutics Announces Partner Boehringer Ingelheim Received U.S. FDA Fast Track Designation for BI 764532 for the Treatment of Extensive Stage Small Cell Lung Cancer and Extrapulmonary Neur... | · BI 764532 is an investigational T-cell engager that redirects T cells towards cancer cells expressing the DLL3 protein |
| 18.09.2023 | ALSA Ventures announces the acquisition of Axovia Therapeutics Inc and the launch of a new portfolio company Axovia Therapeutics Ltd | ·      Developing the first gene therapy to treat diseases caused by cilia dysfunction
·      AXV101 targets retinal dystrophy for Bardet-Biedl Syndrome (BBS) patients
·      FDA Orphan Drug Designation and Rare Paediat... |
| 18.09.2023 | ALSA Ventures announces the acquisition of Axovia Therapeutics Inc and the launch of a new portfolio company Axovia Therapeutics Ltd. | · Developing the first gene therapy to treat diseases caused by cilia dysfunction |
| 31.07.2023 | Epsilogen announces successful completion of first ever clinical trial of an IgE antibody; phase I data for MOv18 IgE demonstrates potential of IgE therapy in cancer | Final results of phase I study of MOv18 IgE in ovarian cancer published in Nature Communications
MOv18 IgE found to be safe and well tolerated with evidence of anti-tumour activity observed |
| 19.07.2023 | ALSA Ventures launches Vantage Biosciences to treat Diabetic Eye Disease | · Diabetic eye diseases are the leading cause of blindness in the working age population |
| 19.10.2022 | Promatix and Jasmin Fisher Lab at University College London Accelerate Hunt for Oncology Therapeutics with New Algorithms for CipherPro. | London, 19 October 2022 – Promatix, a London-based oncology drug discovery and development company that uses multi-omics to identify novel therapeutics, today announced a collaboration with the laboratory of Professor Jasmin Fisher to devel... |
| 03.10.2022 | Oxford BioTherapeutics enters into Commercial License Agreement with Genmab | • OBT licenses to Genmab the rights to a novel, pre-clinical first-in-class immuno-oncology (IO) antibody. |
| 13.06.2022 | Oxford BioTherapeutics Announces Research Collaboration with ImmunoGen to Develop Novel Antibody-Drug Conjugates | • Companies to research Antibody-Drug Conjugates (ADC) to address cancers of high unmet need |
| 27.05.2022 | Oxford BioTherapeutics to Present Initial Positive Data from Phase I Trial at ASCO 2022 | Oxford BioTherapeutics to Present Initial Positive Data from Phase I Trial at ASCO 2022 |
| 25.05.2022 | Oxford BioTherapeutics Announces Collaboration with Agenus to Support the Clinical Development of OBT’s Antibody Drug Conjugate OBT076 in combination with Agenus CPI Balstilimab | Oxford BioTherapeutics Announces Collaboration with Agenus to Support the Clinical Development of OBT’s Antibody Drug Conjugate OBT076 in combination with Agenus CPI Balstilimab |
| 09.05.2022 | Lonza and ALSA Ventures Collaborate to Provide Development and Manufacturing Services for Biotech Firms | |
| 13.04.2022 | Oxford BioTherapeutics Grants Third Exclusive License to Boehringer Ingelheim for Development and Commercialization of Antibody Products to a Novel Oncology Target | Oxford BioTherapeutics Grants Third Exclusive License to Boehringer Ingelheim for Development and Commercialization of Antibody Products to a Novel Oncology Target |
| 07.04.2022 | AACR 2022: Oxford BioTherapeutics to Present Potential Novel Immuno-Oncology Mechanism in Combination with Checkpoint Inhibitors for Experimental ADC Medicine OBT076 | AACR 2022: Oxford BioTherapeutics to Present Potential Novel Immuno-Oncology Mechanism in Combination with Checkpoint Inhibitors for Experimental ADC Medicine OBT076 |
| 22.03.2022 | BioNeex and ALSA Ventures Partner to Provide Biotech Firms a New Way to Drug Candidate Out-Licensing and Acquiring Investment | NEW YORK (PRWEB) MARCH 22, 2022 |
| 02.03.2022 | Epsilogen announces completion of oversubscribed £30.75 million ($41.20 million) Series B financing | Financing led by Novartis Venture Fund and joined by new investors 3B Future Health Fund, British Patient Capital, Schroders Capital and Caribou Property alongside founding investor Epidarex Capital and ALSA Ventures |
| 20.09.2021 | Boehringer Ingelheim and Oxford BioTherapeutics Partnership Advances Second Oncology Drug Candidate into the Clinic | The Boehringer Ingelheim drug candidate was discovered in a partnership with Oxford BioTherapeutics and enabled by Oxford BioTherapeutics’ proprietary OGAP® target discovery platform |
| 14.06.2021 | Montis Biosciences Awarded VLAIO Grant to Expand its Pipeline of Novel Immune-Oncology Therapeutics | Leuven, Belgium, 14 June 2021 -Montis Biosciences, a Belgium-based biotech company focused on the development of novel immuno-oncology therapeutics targeting the interactions between perivascular macrophages and the tumor vasculature, anno... |
| 31.03.2021 | Montis Biosciences appoints René Hoet as Chief Scientific Officer | Dr. Hoet brings 25 years of antibody research and development leadership to his new position as Montis Biosciences’ CSO |
| 08.03.2021 | ALSA Ventures today announced the launch of Promatix Inc., a Delaware incorporated company, to develop novel therapeutics with the potential to transform the treatment of cancer | London, 8 March 2021 – ALSA Ventures today announced the launch of Promatix Inc., a Delaware incorporated company, to develop novel therapeutics with the potential to transform the treatment of cancer. Promatix will use its multi-omic propr... |
| 16.02.2021 | Nature Article Cites IgE Antibodies as a Technology to Watch in 2021 and Notes their Potential as an Anti-Cancer Therapy | Epsilogen is the leading developer of novel IgE antibodies for the treatment of cancer |
| 19.01.2021 | Oxford BioTherapeutics Designates Second Bispecific Antibody Program Leveraging WuXi Biologics’ WuXiBody® Platform | OXFORD, United Kingdom and SAN JOSE, Calif. and SHANGHAI, China, Jan. 19, 2021 (GLOBE NEWSWIRE) -- WuXi Biologics (“WuXi Bio”) (2269.HK), a global company with leading open-access biologics technology platforms, and Oxford BioTherapeutics L... |
| 06.01.2021 | Kite and Oxford BioTherapeutics Establish Cell Therapy Research Collaboration in Blood Cancers and Solid Tumors | Santa Monica, Calif.; Oxford, UK; and San Jose, Calif., January 6 2021 - Kite, a Gilead Company (Nasdaq: GILD), and Oxford BioTherapeutics Ltd. (OBT), a clinical stage oncology company with a pipeline of immuno-oncology (IO) and antibody-dr... |
| 09.11.2020 | Epsilogen Announces Formation of Clinical Advisory Board | Expert oncologists will work with Epsilogen to guide the clinical program for its lead candidate, MOv18 IgE |
| 22.10.2020 | ALSA Ventures webinar: Investing in biotechnology in the COVID era | Thank you to those that joined us for our Webinar last week. For those that missed out and want to hear more about investing in biotech in the COVID era, a recording is available here: https://us02web.zoom.us/rec/share/MM8Yr3F2y9jIoNYKSU49f... |
| 14.10.2020 | Boehringer Ingelheim and Oxford BioTherapeutics Expand Collaboration to Discover Novel Selective Tumor Targets as First Bispecific Antibody Advanced into the Clinic | The collaboration for the discovery of novel selective tumor targets for Boehringer Ingelheim’s unique T-cell engager, cancer vaccine and oncolytic virus platforms, enabled by Oxford BioTherapeutics’ proprietary OGAP® (Oxford Genome Anatomy... |
| 12.10.2020 | ALSA Ventures launches European biotech clinical accelerator 'Eclipse' | |
| 12.10.2020 | ALSA Ventures Launches European Biotech Clinical Accelerator ‘Eclipse’ to speed preclinical assets into the clinic | London, UK – ALSA Ventures, a London based European biotech investment firm today announced the launch of Eclipse, a novel clinical development accelerator focused on therapeutics assets in late preclinical development. |
| 29.09.2020 | Dr. Karen Zinkewich-Péotti brings brings strong R&D leadership experience from both international biopharmaceutical companies and smaller biotech | LEUVEN, BELGIUM, EINPresswire.com -- MONTIS BIOSCIENCES, a discovery stage biotech company focused on novel immuno-oncology therapeutics targeting the interactions between perivascular macrophages and the tumor vasculature, has named Karen ... |
| 22.09.2020 | Ex-CRO boss scores veteran VCs and $59M for his Euro-focused fund | Having worked with hundreds of biotechs as a clinical trial service provider, Novotech founder Alek Safarian is pivoting to a new career in venture capital. |
| 16.09.2020 | ALSA Ventures today announced first closing of its European biotechnology investment fund with commitments of US$59M | London, UK – ALSA Ventures today announced first closing of its European biotechnology investment fund with commitments of US$59M. Established in 2019 by Alek Safarian, founder and ex-CEO of clinical CRO Novotech, the ALSA team has already ... |
| 20.07.2020 | Epsilogen announces further UK government funding to develop next generation antibody treatments for ovarian cancer | London, 20 July 2020 – Epsilogen Ltd, a global leader in the development of novel immunoglobulin E (IgE) antibodies to treat cancer, today announced the award of a £0.5 million grant from the UK’s innovation agency, Innovate UK. Epsilogen w... |
| 30.06.2020 | ALSA Ventures Webinar: European Biotech Investments for Family Offices | Many thanks to all of you who joined us for ALSA Ventures’ webinar on investing in the European biotechnology sector. For those who couldn’t make it, please feel free to watch a recording here. |
| 27.04.2020 | Encouraging interim data from a phase 1 clinical study evaluating MOv18 IgE in cancer patients with advanced solid tumours presented at the AACR Virtual Annual Meeting | MOv18 IgE is the first therapeutic IgE antibody to enter clinical trials |
| 20.04.2020 | Epsilogen licences MOv18 IgE, an anti-folate receptor alpha IgE antibody from King’s College London | MOv18 IgE is currently in phase 1 clinical trial in cancer patients with advanced solid tumours |
| 20.04.2020 | Interim phase 1 data evaluating MOv18 IgE, an anti-folate receptor alpha IgE antibody, in cancer patients with advanced solid tumours to be presented at the AACR Virtual Annual Meeting I | MOv18 IgE is the first therapeutic IgE antibody to enter clinical trials |
| 31.03.2020 | Oxford BioTherapeutics Announces Second Oncology Drug Candidate Selected to Advance into Formal IND Enabling Studies from Boehringer Ingelheim Collaboration | The Boehringer Ingelheim drug candidates are two of several assets approaching or in clinical development whose discovery has been enabled by OBT’s proprietary OGAP® target discovery platform. |
| 20.02.2020 | Montis Biosciences launched with â¬8,4 million seed financing and a novel approach to immune-oncology | Montis was founded by Droia Ventures, VIB and KU Leuven based on the foundational science discovered by the labs of Peter Carmeliet (VIB-KU Leuven) and Massimiliano Mazzone (VIB-KU Leuven). For the seed financing, the founders were joined b... |
| 09.01.2020 | Oxford BioTherapeutics Initiates Dose-Escalation Portion of U.S. Phase I Clinical Trial for OBT076 in Patients with Advanced Solid Tumors | Oxford, UK and San Jose, Calif., January 9 2020 – Oxford BioTherapeutics Ltd. (“OBT”), a clinical stage oncology company developing antibody-based immuno-oncology therapies emerging from the Company’s proprietary target discovery platform, ... |
| 27.08.2019 | IGEM Therapeutics announces final close of £5 million Series A financing round | London, November 30th, 2018– IGEM Therapeutics (IGEM or “the Company”), an immuno-oncology company developing novel immunoglobulin E (IgE) antibodies to treat cancer, announced it has secured an additional £3 million to close its Series A r... |
